Global Alpha Capital Management’s Emergent Biosolutions EBS Stock Holding History

Global Alpha Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-606,550	Closed	-$12.7M	–	37
2022 Q3	$12.7M	Buy	606,550 +188,520	+45%	+$5.25M	1.27%	31
2022 Q2	$13M	Sell	418,030 -42,500	-9%	-$1.45M	1.4%	27
2022 Q1	$18.9M	Buy	460,530 +130,260	+39%	+$5.75M	1.62%	28
2021 Q4	$14.4M	Sell	330,270 -9,710	-3%	-$439K	1.39%	29
2021 Q3	$17M	Buy	+339,980	New	+$20.6M	1.89%	25

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Global Alpha Capital Management's EBS Position: Q4 2022 in Review

Global Alpha Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 606,550 shares — an estimated $12.7M sold.

Global Alpha Capital Management first reported a position in EBS in Q3 2021 and held it in 5 quarters. The position peaked at $18.9M in Q1 2022. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

Global Alpha Capital Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
Global Alpha Capital Management sold 606,550 Emergent Biosolutions shares in Q4 2022, an estimated $12.7M.
Global Alpha Capital Management first reported a position in Emergent Biosolutions in Q3 2021 and held it in 5 quarters.
Global Alpha Capital Management's Emergent Biosolutions position peaked at $18.9M in Q1 2022.
198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Global Alpha Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.